194 related articles for article (PubMed ID: 27595330)
1. Small-molecule WNK inhibition regulates cardiovascular and renal function.
Yamada K; Park HM; Rigel DF; DiPetrillo K; Whalen EJ; Anisowicz A; Beil M; Berstler J; Brocklehurst CE; Burdick DA; Caplan SL; Capparelli MP; Chen G; Chen W; Dale B; Deng L; Fu F; Hamamatsu N; Harasaki K; Herr T; Hoffmann P; Hu QY; Huang WJ; Idamakanti N; Imase H; Iwaki Y; Jain M; Jeyaseelan J; Kato M; Kaushik VK; Kohls D; Kunjathoor V; LaSala D; Lee J; Liu J; Luo Y; Ma F; Mo R; Mowbray S; Mogi M; Ossola F; Pandey P; Patel SJ; Raghavan S; Salem B; Shanado YH; Trakshel GM; Turner G; Wakai H; Wang C; Weldon S; Wielicki JB; Xie X; Xu L; Yagi YI; Yasoshima K; Yin J; Yowe D; Zhang JH; Zheng G; Monovich L
Nat Chem Biol; 2016 Nov; 12(11):896-898. PubMed ID: 27595330
[TBL] [Abstract][Full Text] [Related]
2. Leveraging unique structural characteristics of WNK kinases to achieve therapeutic inhibition.
Zhang J; Deng X; Kahle KT
Sci Signal; 2016 Oct; 9(450):e3. PubMed ID: 27811182
[TBL] [Abstract][Full Text] [Related]
3. Investigating specificity of the anti-hypertensive inhibitor WNK463 against With-No-Lysine kinase family isoforms via multiscale simulations.
Jonniya NA; Kar P
J Biomol Struct Dyn; 2020 Mar; 38(5):1306-1321. PubMed ID: 31017050
[TBL] [Abstract][Full Text] [Related]
4. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.
Yamada K; Levell J; Yoon T; Kohls D; Yowe D; Rigel DF; Imase H; Yuan J; Yasoshima K; DiPetrillo K; Monovich L; Xu L; Zhu M; Kato M; Jain M; Idamakanti N; Taslimi P; Kawanami T; Argikar UA; Kunjathoor V; Xie X; Yagi YI; Iwaki Y; Robinson Z; Park HM
J Med Chem; 2017 Aug; 60(16):7099-7107. PubMed ID: 28771350
[TBL] [Abstract][Full Text] [Related]
5. Cheminformatics Analysis of Dynamic WNK-Inhibitor Interactions.
Kuenemann MA; Fourches D
Mol Inform; 2018 Jul; 37(6-7):e1700138. PubMed ID: 29473325
[TBL] [Abstract][Full Text] [Related]
6. The role of WNK in modulation of KCl cotransport activity in red cells from normal individuals and patients with sickle cell anaemia.
Lu DC; Hannemann A; Wadud R; Rees DC; Brewin JN; Low PS; Gibson JS
Pflugers Arch; 2019 Dec; 471(11-12):1539-1549. PubMed ID: 31729557
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Characterization of Allosteric WNK Kinase Inhibitors.
Yamada K; Zhang JH; Xie X; Reinhardt J; Xie AQ; LaSala D; Kohls D; Yowe D; Burdick D; Yoshisue H; Wakai H; Schmidt I; Gunawan J; Yasoshima K; Yue QK; Kato M; Mogi M; Idamakanti N; Kreder N; Drueckes P; Pandey P; Kawanami T; Huang W; Yagi YI; Deng Z; Park HM
ACS Chem Biol; 2016 Dec; 11(12):3338-3346. PubMed ID: 27712055
[TBL] [Abstract][Full Text] [Related]
8. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
9. WNK kinases and the kidney.
Hoorn EJ; Ellison DH
Exp Cell Res; 2012 May; 318(9):1020-6. PubMed ID: 22405999
[TBL] [Abstract][Full Text] [Related]
10. Towards the Development of Small-Molecule MO25 Binders as Potential Indirect SPAK/OSR1 Kinase Inhibitors.
Kadri H; Alamri MA; Navratilova IH; Alderwick LJ; Simpkins NS; Mehellou Y
Chembiochem; 2017 Mar; 18(5):460-465. PubMed ID: 28004876
[TBL] [Abstract][Full Text] [Related]
11. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
12. Identification and further development of potent TBK1 inhibitors.
Richters A; Basu D; Engel J; Ercanoglu MS; Balke-Want H; Tesch R; Thomas RK; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):289-98. PubMed ID: 25540906
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
14. Identification of peptide substrate and small molecule inhibitors of testis-specific serine/threonine kinase1 (TSSK1) by the developed assays.
Zhang L; Yan Y; Liu Z; Abliz Z; Liu G
J Med Chem; 2009 Jul; 52(14):4419-28. PubMed ID: 19530700
[TBL] [Abstract][Full Text] [Related]
15. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
Doe C; Bentley R; Behm DJ; Lafferty R; Stavenger R; Jung D; Bamford M; Panchal T; Grygielko E; Wright LL; Smith GK; Chen Z; Webb C; Khandekar S; Yi T; Kirkpatrick R; Dul E; Jolivette L; Marino JP; Willette R; Lee D; Hu E
J Pharmacol Exp Ther; 2007 Jan; 320(1):89-98. PubMed ID: 17018693
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases.
Huang L; Be X; Berry L; Moore E; Janosky B; Wells M; Pan WJ; Zhao Z; Lin MH
Xenobiotica; 2011 May; 41(5):400-8. PubMed ID: 21294625
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats.
Nishikimi T; Koshikawa S; Ishikawa Y; Akimoto K; Inaba C; Ishimura K; Ono H; Matsuoka H
J Hypertens; 2007 May; 25(5):1053-63. PubMed ID: 17414670
[TBL] [Abstract][Full Text] [Related]
18. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.
Fuji RN; Flagella M; Baca M; Baptista MA; Brodbeck J; Chan BK; Fiske BK; Honigberg L; Jubb AM; Katavolos P; Lee DW; Lewin-Koh SC; Lin T; Liu X; Liu S; Lyssikatos JP; O'Mahony J; Reichelt M; Roose-Girma M; Sheng Z; Sherer T; Smith A; Solon M; Sweeney ZK; Tarrant J; Urkowitz A; Warming S; Yaylaoglu M; Zhang S; Zhu H; Estrada AA; Watts RJ
Sci Transl Med; 2015 Feb; 7(273):273ra15. PubMed ID: 25653221
[TBL] [Abstract][Full Text] [Related]
19. WNK kinases and the control of blood pressure.
Cope G; Golbang A; O'Shaughnessy KM
Pharmacol Ther; 2005 May; 106(2):221-31. PubMed ID: 15866321
[TBL] [Abstract][Full Text] [Related]
20. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
